James Wang, MD
Gastroenterology · Everett, WANPI 1376606194
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 39.3% of the total. That places this record below the midpoint for gastroenterology clinicians in WA, where the typical reported total is $517.
Across 23 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$213
- Takeda Pharmaceuticals U.S.A., Inc.$138
- Sanofi$61
- Aimmune Therapeutics, Inc.$39
- Regeneron Healthcare Solutions, Inc.$28
- Celltrion USA Inc.$26
- plus $37 from 2 others
What the payments were for
- Food & beverage$541100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $138 |
| Sanofi | 2 | $61 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Celltrion USA Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Pfizer | 1 | $17 |
How this compares
$541 in reported general payments places this provider in the 50th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 13 | $46,743 |
| Mesalamine | 24 | $12,951 |
| Amjevita(Cf) AutoinjectorAdalimumab-Atto | 12 | $10,902 |
| Omeprazole | 172 | $3,641 |
| Colestipol Hcl | 20 | $2,028 |
| Budesonide DrBudesonide | 16 | $1,574 |
| Esomeprazole Magnesium | 20 | $1,291 |
| Tenofovir Disoproxil Fumarate | 12 | $885 |
| Dicyclomine Hcl | 26 | $877 |
| Rabeprazole Sodium | 23 | $785 |
| Famotidine | 36 | $781 |
| Pantoprazole Sodium | 35 | $394 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 11 | $289 |
| LoperamideLoperamide Hcl | 15 | $207 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Everett
- Michael ChioreanIssaquah$1.4M
- Kris KowdleySeattle$1.4M
- Venkatachala MohanBellevue$564K
- Scott LeeSeattle$220K
- John SunTacoma$219K
- Klaus MergenerEdmonds$185K
- Alyssa ChoiSeattle$102K
- Andrew RossSeattle$99K
- Jaime Aranda-MichelVancouver$82K
- Christian HornTacoma$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.